BH3 mimetics are a class of anticancer agents that hold the promise to trigger the central apoptotic machinery to set cancer cells on the road to ruin. Now, a new agent that selectively targets BCL-2, ABT-199, has been developed, with exciting preclinical and clinical results (pages 202–208).
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
BMC Cancer Open Access 03 November 2023
-
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Drugs Open Access 29 November 2017
-
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
Oncogene Open Access 17 October 2016
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Souers, A.J. et al. Nat. Med. 19, 202–208 (2013).
Green, D.R. Means to an End: Apoptosis and Other Cell Death Mechanisms (CSHL Press, 2011).
Chipuk, J.E., Moldoveanu, T., Llambi, F., Parsons, M.J. & Green, D.R. Mol. Cell 37, 299–310 (2010).
Vo, T.T. et al. Cell 151, 344–355 (2012).
Oltersdorf, T. et al. Nature 435, 677–681 (2005).
Tse, C. et al. Cancer Res. 68, 3421–3428 (2008).
van Delft, M.F. et al. Cancer Cell 10, 389–399 (2006).
Mason, K.D. et al. Cell 128, 1173–1186 (2007).
Beroukhim, R. et al. Nature 463, 899–905 (2010).
Gavathiotis, E., Reyna, D.E., Bellairs, J.A., Leshchiner, E.S. & Walensky, L.D. Nat. Chem. Biol. 8, 639–645 (2012).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Green, D., Walczak, H. Apoptosis therapy: driving cancers down the road to ruin. Nat Med 19, 131–133 (2013). https://doi.org/10.1038/nm.3076
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.3076
This article is cited by
-
Efficacy and safety of venetoclax in patients with relapsed/refractory multiple myeloma: a meta-analysis
BMC Cancer (2023)
-
Zinc-Phosphate Nanoparticles as a Novel Anticancer Agent: An In Vitro Evaluation of Their Ability to Induce Apoptosis
Biological Trace Element Research (2020)
-
Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update
Drugs (2018)
-
Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells
Oncogene (2017)
-
Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199
Leukemia (2014)